Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Wiesbeck, G. A.
Right arrow Articles by Boening, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiesbeck, G. A.
Right arrow Articles by Boening, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Alcohol and Alcoholism Vol. 35, No. 4, pp. 384-389, 2000
© 2000 Medical Council on Alcoholism

THE EFFECTS OF RITANSERIN ON MOOD, SLEEP, VIGILANCE, CLINICAL IMPRESSION, AND SOCIAL FUNCTIONING IN ALCOHOL-DEPENDENT INDIVIDUALS

G. A. Wiesbeck*, H.-G. Weijers, J. Chick1, J. Boening and on behalf of The Ritanserin in Alcoholism Work Group2

Alcohol Research Program, Psychiatric Clinic, University of Wuerzburg, Germany and
1 Alcohol Problems Clinic, 35 Morningside Park, Edinburgh, UK

Received 7 January 1999; first review notified 1 March 2000; accepted 28 March 2000

In an international double-blind placebo-controlled trial with 493 detoxified alcohol-dependent individuals, ritanserin, a specific 5-hydroxytryptamine2 antagonist, was tested in three different dosages (2.5, 5, and 10 mg/day) against placebo over a period of 6 months. Data on changes in mood state, sleep quality, morning vigilance, clinical impression, and social functioning were analysed. None of the three dosages of ritanserin given revealed any significant effect against placebo on the above-mentioned parameters either at the end of treatment or upon relapse. Therefore, we conclude that patients suffering from alcohol dependence without concomitant psychiatric disorders do not benefit from additional treatment with (2.5, 5, or 10 mg/day) ritanserin.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.